
    
      This is a pilot phase II trial of the combination of concurrent hypofractionated IMRT (60
      Gy/2 weeks), temozolomide and bevacizumab followed by 6 cycles of adjuvant bevacizumab and
      temozolomide in patients with grade IV malignant gliomas (glioblastoma and gliosarcoma). The
      study will have survival and toxicity endpoints.
    
  